Accredited Investors Employee Shareholders Institutions Private Companies Who We Serve Trading and InvestingData SolutionsPrivate Asset Custody Institutional TradingForge ProTrade private companies with Forge’s institutional brokerage toolBrowse CompaniesIndividual InvestingForge MarketsFind new private company investment opportunitiesForge DataAnalyze private markets via Forge’s intuitive web applicationForge Private Market IndexMonitor a benchmark for actively traded private companies Forge Accuidity Private Market IndexInvest in an institutionally-managed diversified basket of private companies (QPs only)Self-Directed IRAForge TrustInvest in private companies and other alternative assets through a tax-advantaged Self-Directed IRASolutions All InsightsPrivate Market ReportsMarket InsightsBuying and Selling Pre-IPO All ReportsPrivate Market Updates Forge Investment OutlookStartup News and TrendsPrivate Market Data and AnalyticsTech IPO Calendar for 2024Private Market ExplainedBuying Pre-IPO SharesSelling Pre-IPO Shares Glossary Videos FAQsInsights About Us Leadership Investor Relations People & Culture Careers About

BlueRock Therapeutics Stock

Q: How to sell BlueRock Therapeutics stock?

If you hold private company shares of BlueRock Therapeutics - whether as an employee or an early investor - Forge can help you sell them. 1. Create a free Forge account, this will give you access to Forge’s marketplace and to one of our experienced Private Market Specialist to answer any questions you might have. 2. Indicate your interest to sell your BlueRock Therapeutics stock on our platform. 3. Work with your dedicated Private Market Specialist who’ll help guide you through every step of the transaction.

bluerocktx.comHealthcare / BioTech & PharmaFounded: 2016Funding to Date: $225MM

BlueRock Therapeutics is an engineered cell therapy company with a mission to develop regenerative medicines for intractable diseases with a platform that harnesses the power of cells for new medicines across neurology, cardiology and autoimmune indications.

Buy or sell BlueRock Therapeutics stockLearn more about BlueRock Therapeutics IPO

OverviewFinancingsValuation

Enterprise Value

Access BlueRock Therapeutics’ valuation and stock price.

View secondary pricing information, VWAP and distribution waterfall. And seek potentially outsized returns with same day private market data for private companies like BlueRock Therapeutics.

Become part of the Secondary Marketplace, catering to both individual and institutional investors.

Access Stock Price

Animation displayed is not current and securities are shown for illustrative purposes only.

Team

Management Team

Emile Nuwaysir Ph.D

Chief Executive Officer, President & Board Member

Gordon Keller Ph.D

Scientific Co-Founder

Shane Kovacs

Chief Business and Financial Officer

Min Wang Ph.D

Chief Administrative & Legal Officer

Lorenz Studer Ph.D

Scientific Co-Founder

Robert Deans Ph.D

Chief Technology Officer

Joachim Fruebis Ph.D

Chief Development Officer

Michael Scott Ph.D

Senior Vice President, Product Development

Board Members

Bradley Bolzon Ph.D

Versant Venture Management

Jerel Davis Ph.D

Versant Venture Management

Jurg Eckardt MD

Axel Bouchon

BlueRock Therapeutics stock FAQs

Can you buy BlueRock Therapeutics stock?

As BlueRock Therapeutics is not publicly traded, purchasing its stock is not available to everyone. To buy the stock of a private company like BlueRock Therapeutics, you must be an accredited investor. If you meet the accreditation criteria, you can register for Forge’s Secondary Marketplace to buy private market stock. If you are not an accredited investor, discover how to begin the process to potentially qualify for new investment opportunities.

How to buy BlueRock Therapeutics stock?

To invest in a private company like BlueRock Therapeutics through Forge, you must first qualify as an accredited investor. (Learn more about the accreditation process.)

Create a free account to access Forge’s marketplace.
Express your interest in specific investments. Within Forge Markets, you will find detailed pricing and financing information for thousands of private companies.
Throughout this process, a dedicated Forge Private Market Specialist will be available to address any questions you may have and to guide you seamlessly through each step of the transaction.

Can you sell BlueRock Therapeutics stock?

Yes, you may be able to sell your BlueRock Therapeutics stock, subject to certain conditions. Forge can help you facilitate the sale of your stock in a manner that aligns with your needs and the company's interests. If you are looking for liquidity, register with us today to begin the process. A dedicated Forge Private Market Specialist will be available to address any questions you may have along the way.

How to sell BlueRock Therapeutics stock?

If you hold private company shares of - whether as an employee or an early investor - Forge can help you sell them.

Create a free Forge account, this will give you access to Forge’s marketplace and to one of our experienced Private Market Specialist to answer any questions you might have.
Indicate your interest to sell your BlueRock Therapeutics stock on our platform.
Work with your dedicated Private Market Specialist who'll help guide you through every step of the transaction.

Is BlueRock Therapeutics a public company?

No, BlueRock Therapeutics is a privately held company and is currently not publicly traded on any stock markets including NYSE or NASDAQ.

What is BlueRock Therapeutics’ stock price?

BlueRock Therapeutics is a privately held company and therefore does not have a public stock price. However, you may access BlueRock Therapeutics’ private market stock price with Forge Data.

What is BlueRock Therapeutics’ stock ticker symbol?

BlueRock Therapeutics does not have an official ticker symbol because this company is not currently publicly traded.

Can institutional investors buy and sell private market stocks?

Yes. As one of the largest trading platform for the private market, Forge helps institutional investors seek liquidity as they buy and sell private stock for their portfolios or their clients. Our private market specialists have decades of experience working with institutional firms. Learn more or register today to get started.

Fierce Pharma 10/10/2023

Bayer christens $250M cell therapy 'launch facility' in Berkeley

Bayer AG and its subsidiary, BlueRock Therapeutics, have reported positive early-stage results for their experimental Parkinson's disease stem cell therapy, bemdaneprocel. The treatment was well-tolerated in all 12 patients in the phase 1 study and showed potential to reform neural networks and restore motor and non-motor function. Following these results, a phase 2 study is planned for the first half of 2024.

Reuters 08/25/2023

Bayer claims early lead in Parkinson's stem cell therapy

Bayer's subsidiary BlueRock is leading the way in Parkinson's stem cell therapy. In a Phase I trial, BlueRock's therapy was well tolerated and the cells grew as expected in patients' brains. This has prompted the company to progress to the second stage of testing, with patient enrollment expected in the first half of 2024.

Browse More Insights

Frequently Asked Questions

Updated on: Jul 26, 2024

PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES

Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.